




# PHARMACEUTICAL 2023

**AILERON THERAPEUTICS INC**  
Rank 261 of 446





# PHARMACEUTICAL 2023

## AILERON THERAPEUTICS INC Rank 261 of 446

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 6.2% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,873
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,384
Liabilities, Non-Current	0
Other Assets	64
Other Compr. Net Income	-35
Other Expenses	0
Other Liabilities	0
Other Net Income	318
Other Revenues	0
Property and Equipment	70
Research and Development	17,967
Selling, General and Administrative Expense	9,680

Output Variable	Value in 1000 USD
Assets	22,007
Liabilities	3,384
Expenses	27,647
Revenues	0
Stockholders Equity	18,623
Net Income	-27,329
Comprehensive Net Income	-27,346
Economic Capital Ratio	37%